Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Yizhuo Zhao, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Robert Pirker, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Yan Sun

JAMA Oncology, 2018

Shanghai Chest Hospital, Tianjin Medical University Cancer Institute and Hospital, Zhengzhou University, Henan Cancer Hospital, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Shandong Tumor Hospital, Shandong First Medical University, Jilin Province Tumor Hospital, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Nanjing Medical University, Lanzhou Army General Hospital, Hunan Cancer Hospital, Qilu Hospital of Shandong University, Medical University of Vienna, First Affiliated Hospital of Xi'an Jiaotong University, Tang Du Hospital, Capital Medical University, Beijing Chest Hospital

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with JAMA Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

606

Citations

View on Google Scholar

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back